Peptide having HTLV-1-specific CTL-inducing activity
    10.
    发明申请
    Peptide having HTLV-1-specific CTL-inducing activity 审中-公开
    具有HTLV-1特异性CTL诱导活性的肽

    公开(公告)号:US20060111551A1

    公开(公告)日:2006-05-25

    申请号:US11251195

    申请日:2005-10-14

    摘要: The present invention provides a peptide having HTLV-I-specific CTL-inducing activity that can induce cytotoxic T cells (CTL) having anti-tumor effect to human T cell leukemia virus-I (HTLV-I) tumor such as adult T-cell leukemia (ATL); a vaccine to induce immune response by using these; a diagnostic agent to examine immune function or the like. By investigating cellular immune response of ATL patient having obtained complete remission after hematopoietic stem cell transplantation (HSCT) from a HLA-identical sibling donor, HTLV-I-specific CTLs were induced only to HLA-A2 restricted Tax301-309 epitope that have proliferated actively by responding to auto-HTLV-I infected T cells constructed in vitro before HSCT, in the culture solution of peripheral blood mononuclear cells (PBMC) of post-HSCT ATL patient. This suggests that this epitope was strongly expressed in the patient body suggesting that the epitope is useful as vaccine antigen.

    摘要翻译: 本发明提供具有HTLV-1特异性CTL诱导活性的肽,其能够诱导对人T细胞白血病病毒I(HTLV-1)肿瘤具有抗肿瘤作用的细胞毒性T细胞(CTL),例如成人T细胞 白血病(ATL); 通过使用这些疫苗诱导免疫反应; 检查免疫功能等的诊断剂。 通过研究来自HLA相同同胞供者的造血干细胞移植(HSCT)获得完全缓解的ATL患者的细胞免疫应答,HTLV-1特异性CTL仅诱导积极增殖的HLA-A2限制性的Tax301-309表位 通过在HSCT ATL患者的外周血单核细胞(PBMC)的培养液中响应在HSCT之前体外构建的自身HTLV-1感染的T细胞。 这表明该表位在患者体内强烈表达,表明表位可用作疫苗抗原。